Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients

被引：16

作者：

Kim, Hong Jun ^{[1
]}

Jo, Min Jee ^{[2
]}

Kim, Bo Ram ^{[2
]}

Kim, Jung Lim ^{[2
]}

Jeong, Yoon A. ^{[2
]}

Na, Yoo Jin ^{[2
]}

Park, Seong Hye ^{[2
]}

Lee, Suk-young ^{[1
]}

Lee, Dae-Hee ^{[1
,2
]}

Kim, Baek-hui ^{[3
]}

Yoo, Young Do ^{[4
]}

Oh, Sang Cheul ^{[1
,2
]}

机构：

[1] Korea Univ, Dept Internal Med, Coll Med, Div Oncol & Hematol, Seoul, South Korea

[2] Korea Univ, Grad Sch Med, Lab Oncol, Seoul, South Korea

[3] Korea Univ, Dept Pathol, Coll Med, Seoul, South Korea

[4] Korea Univ, Grad Sch Med, Lab Mol Cell Biol, Seoul, South Korea

来源：

ONCOTARGETS AND THERAPY | 2018年 / 11卷

关键词：

non-small cell lung carcinoma; inflammation; reactive oxygen species modulator-1; vascular endothelial growth factor A; reactive oxygen species; OXIDATIVE STRESS; ROS; INFLAMMATION; STATISTICS; MORTALITY; SURVIVAL; INVASION; DISEASE; VEGF;

D O I：

10.2147/OTT.S161587

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: Reactive oxygen species modulator-1 (Romo1) is a protein that modulates levels of reactive oxygen species (ROS) and has been reported to affect cancer cell invasion and proliferation via persistent inflammation. Several studies have demonstrated the clinical application of Romol as a prognostic marker in non-small cell lung cancer (NSCLC); however, there have been no studies investigating the mechanism by which Romo1 adversely affects the prognosis of these patients. Methods: We examined Romo1, ROS, and vascular endothelial growth factor (VEGF) in tumor tissues immunohistochemically. We conducted survival analyses of patients who had curative resection (n=30) in accordance with clinical parameters including levels of Romo1 expression. Results: Romo 1 levels were associated with serologic inflammatory markers and high lymphatic metastatic tendencies. Significantly longer disease-free survival (68.7 vs 24.2 months, P=0.031) and overall survival (92.7 vs 51.6 months) were observed in the group with low Romol compared with high Romol. Survival outcomes were also significantly associated with serologic inflammatory markers. Spearman's correlation analyses demonstrated significant positive correlations of Romol expression with VEGF-C (P=0.008, R=0.478) and ROS (P=0.016, R=0.436) in tumor samples. Conclusion: The current study demonstrates that Romo1 induces lymphatic metastasis of NSCLC by modulating persistent inflammation and oxidative stress (ROS)/VEGF signaling. Lymphatic metastasis associated with elevated Romo1 was shown to be a key reason for unfavorable survival rates.

引用

页码：4233 / 4246

页数：14